The global retinitis pigmentosa (RP) market was valued at USD 14.02 billion in 2023 and is expected to grow significantly, reaching USD 21.40 billion by 2033. This growth represents a compound annual growth rate (CAGR) of 6.2% from 2023 to 2033.
In 2023, autosomal recessive RP was the dominant form, accounting for 65% of the market share. However, gene therapy is gaining attention, with a promising 23% market share, offering new hope for many patients.
Currently, North America holds the largest share of the RP market, but Asia Pacific is experiencing the fastest growth, potentially reshaping the market’s future dynamics.
Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5114
In 2022, it was estimated that between 82,500 and 110,000 people in the United States were living with retinitis pigmentosa (RP), highlighting the increasing need for new treatments, such as gene therapy and retinal implants.
Retinitis pigmentosa refers to a group of genetic eye disorders that affect the retina, the part of the eye responsible for vision. The condition causes the gradual deterioration of photoreceptor cells, which are essential for seeing in different lighting conditions and maintaining clear vision. As RP progresses, people often experience difficulty seeing in low-light or at night, a loss of peripheral vision, and, in some cases, complete blindness.
There are two main types of retinitis pigmentosa: non-syndromic and syndromic. Non-syndromic RP, which accounts for 70-80% of cases, does not involve other systemic health issues. On the other hand, syndromic RP, which makes up 20-30% of cases, is linked to additional health conditions outside of the eyes. Non-syndromic RP is caused by mutations in about 80 different genes, with 20% of cases being autosomal recessive, 10-20% autosomal dominant (AD), and 10% X-linked recessive.
A 2021 study by the National Institutes of Health, conducted in Spain (which has one of the largest patient populations for inherited retinal diseases), also found new insights into X-linked retinitis pigmentosa (XLRP). While it was previously thought that only males were affected by XLRP, it is now recognized that female carriers can also show symptoms, ranging from mild to severe retinal disease. The remaining cases of RP are considered “sporadic,” meaning no clear inheritance pattern or molecular cause has been identified.
In January 2022, 4D Molecular Therapeutics announced that the FDA had granted special status to 4D-125, a promising treatment for X-linked retinitis pigmentosa (XLRP). This therapy is designed to deliver a functional version of the RPGR gene directly to the retina’s light-sensitive cells and is formulated for easy administration into the eye.
Also in 2022, Bionic Vision Technologies (BVT) received Breakthrough Device designation from the FDA for their Bionic Eye System. This recognition marks a major step forward in the field of bionic vision technology, with the system offering hope for people with severe vision impairments.
In the Netherlands, a patient underwent the first procedure to receive the Prima System, a bionic eye implant developed by Pixium Vision in France. This innovative implant holds promise for people suffering from geographic atrophy (GA), a form of dry age-related macular degeneration (AMD), offering the potential for partial vision restoration.
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/retinitis-pigmentosa-market-sizing
Access exclusive insight now @ https://www.towardshealthcare.com/price/5114
We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com
Web: https://www.towardshealthcare.com
Visit Dental Specifics: https://www.towardsdental.com
Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
Contract Development and Manufacturing Organizations (CDMOs) play a crucial role in the pharmaceutical and biotechnology industries by providing essential services… Read More
The global medical rehabilitation services market has been experiencing significant expansion, driven by various factors such as an aging population,… Read More
The global antibody drug market is experiencing rapid growth, with a notable surge in monoclonal antibody (mAb) demand. The market… Read More
Stroke rehabilitation plays a crucial role in helping individuals regain independence and improve their quality of life following a stroke.… Read More
Healthcare is a multifaceted domain, catering to various needs and conditions. The concept of ambulatory wellness services, which focus on… Read More
Artificial Intelligence (AI) and Machine Learning (ML) have rapidly evolved from emerging technologies to integral components in a variety of… Read More